Cargando…
Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
BACKGROUND: Stimulation of β(2)‐adrenoceptors can promote muscle hypertrophy and fibre type shift, and it can counteract atrophy and weakness. The underlying mechanisms remain elusive. METHODS: Fed wild type (WT), 2‐day fasted WT, muscle‐specific insulin (INS) receptor (IR) knockout (M‐IR(−/−)), and...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463755/ https://www.ncbi.nlm.nih.gov/pubmed/30932373 http://dx.doi.org/10.1002/jcsm.12395 |
_version_ | 1783410806917955584 |
---|---|
author | Gonçalves, Dawit A. Silveira, Wilian A. Manfredi, Leandro H. Graça, Flávia A. Armani, Andrea Bertaggia, Enrico O´Neill, Brian T. Lautherbach, Natalia Machado, Juliano Nogara, Leonardo Pereira, Marcelo G. Arcidiacono, Diletta Realdon, Stefano Kahn, C. Ronald Sandri, Marco Kettelhut, Isis C. Navegantes, Luiz Carlos C. |
author_facet | Gonçalves, Dawit A. Silveira, Wilian A. Manfredi, Leandro H. Graça, Flávia A. Armani, Andrea Bertaggia, Enrico O´Neill, Brian T. Lautherbach, Natalia Machado, Juliano Nogara, Leonardo Pereira, Marcelo G. Arcidiacono, Diletta Realdon, Stefano Kahn, C. Ronald Sandri, Marco Kettelhut, Isis C. Navegantes, Luiz Carlos C. |
author_sort | Gonçalves, Dawit A. |
collection | PubMed |
description | BACKGROUND: Stimulation of β(2)‐adrenoceptors can promote muscle hypertrophy and fibre type shift, and it can counteract atrophy and weakness. The underlying mechanisms remain elusive. METHODS: Fed wild type (WT), 2‐day fasted WT, muscle‐specific insulin (INS) receptor (IR) knockout (M‐IR(−/−)), and MKR mice were studied with regard to acute effects of the β(2)‐agonist formoterol (FOR) on protein metabolism and signalling events. MKR mice express a dominant negative IGF1 receptor, which blocks both INS/IGF1 signalling. All received one injection of FOR (300 μg kg(−1) subcutaneously) or saline. Skeletal muscles and serum samples were analysed from 30 to 240 min. For the study of chronic effects of FOR on muscle plasticity and function as well as intracellular signalling pathways, fed WT and MKR mice were treated with formoterol (300 μg kg(−1) day(−1)) for 30 days. RESULTS: In fed and fasted mice, one injection of FOR inhibited autophagosome formation (LC3‐II content, 65%, P ≤ 0.05) that was paralleled by an increase in serum INS levels (4‐fold to 25‐fold, P ≤ 0.05) and the phosphorylation of Akt (4.4‐fold to 6.5‐fold, P ≤ 0.05) and ERK1/2 (50% to two‐fold, P ≤ 0.05). This led to the suppression (40–70%, P ≤ 0.05) of the master regulators of atrophy, FoxOs, and the mRNA levels of their target genes. FOR enhanced (41%, P ≤ 0.05) protein synthesis only in fed condition and stimulated (4.4‐fold to 35‐fold, P ≤ 0.05) the prosynthetic Akt/mTOR/p70S6K pathway in both fed and fasted states. FOR effects on Akt signalling during fasting were blunted in both M‐IR(−/−) and MKR mice. Inhibition of proteolysis markers by FOR was prevented only in MKR mice. Blockade of PI3K/Akt axis and mTORC1, but not ERK1/2, in fasted mice also suppressed the acute FOR effects on proteolysis and autophagy. Chronic stimulation of β(2)‐adrenoceptors in fed WT mice increased body (11%, P ≤ 0.05) and muscle (15%, P ≤ 0.05) growth and downregulated atrophy‐related genes (30–40%, P ≤ 0.05), but these effects were abolished in MKR mice. Increases in muscle force caused by FOR (WT, 24%, P ≤ 0.05) were only partially impaired in MKR mice (12%, P ≤ 0.05), and FOR‐induced slow‐to‐fast fibre type shift was not blocked at all in these animals. In MKR mice, FOR also restored the lower levels of muscle SDH activity to basal WT values and caused a marked reduction (57%, P ≤ 0.05) in the number of centrally nucleated fibers. CONCLUSIONS: NS/IGF1 signalling is necessary for the anti‐proteolytic and hypertrophic effects of in vivo β(2)‐adrenergic stimulation and appears to mediate FOR‐induced enhancement of protein synthesis. INS/IGF1 signalling only partially contributes to gain in strength and does not mediate fibre type transition induced by FOR. |
format | Online Article Text |
id | pubmed-6463755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64637552019-04-22 Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth Gonçalves, Dawit A. Silveira, Wilian A. Manfredi, Leandro H. Graça, Flávia A. Armani, Andrea Bertaggia, Enrico O´Neill, Brian T. Lautherbach, Natalia Machado, Juliano Nogara, Leonardo Pereira, Marcelo G. Arcidiacono, Diletta Realdon, Stefano Kahn, C. Ronald Sandri, Marco Kettelhut, Isis C. Navegantes, Luiz Carlos C. J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Stimulation of β(2)‐adrenoceptors can promote muscle hypertrophy and fibre type shift, and it can counteract atrophy and weakness. The underlying mechanisms remain elusive. METHODS: Fed wild type (WT), 2‐day fasted WT, muscle‐specific insulin (INS) receptor (IR) knockout (M‐IR(−/−)), and MKR mice were studied with regard to acute effects of the β(2)‐agonist formoterol (FOR) on protein metabolism and signalling events. MKR mice express a dominant negative IGF1 receptor, which blocks both INS/IGF1 signalling. All received one injection of FOR (300 μg kg(−1) subcutaneously) or saline. Skeletal muscles and serum samples were analysed from 30 to 240 min. For the study of chronic effects of FOR on muscle plasticity and function as well as intracellular signalling pathways, fed WT and MKR mice were treated with formoterol (300 μg kg(−1) day(−1)) for 30 days. RESULTS: In fed and fasted mice, one injection of FOR inhibited autophagosome formation (LC3‐II content, 65%, P ≤ 0.05) that was paralleled by an increase in serum INS levels (4‐fold to 25‐fold, P ≤ 0.05) and the phosphorylation of Akt (4.4‐fold to 6.5‐fold, P ≤ 0.05) and ERK1/2 (50% to two‐fold, P ≤ 0.05). This led to the suppression (40–70%, P ≤ 0.05) of the master regulators of atrophy, FoxOs, and the mRNA levels of their target genes. FOR enhanced (41%, P ≤ 0.05) protein synthesis only in fed condition and stimulated (4.4‐fold to 35‐fold, P ≤ 0.05) the prosynthetic Akt/mTOR/p70S6K pathway in both fed and fasted states. FOR effects on Akt signalling during fasting were blunted in both M‐IR(−/−) and MKR mice. Inhibition of proteolysis markers by FOR was prevented only in MKR mice. Blockade of PI3K/Akt axis and mTORC1, but not ERK1/2, in fasted mice also suppressed the acute FOR effects on proteolysis and autophagy. Chronic stimulation of β(2)‐adrenoceptors in fed WT mice increased body (11%, P ≤ 0.05) and muscle (15%, P ≤ 0.05) growth and downregulated atrophy‐related genes (30–40%, P ≤ 0.05), but these effects were abolished in MKR mice. Increases in muscle force caused by FOR (WT, 24%, P ≤ 0.05) were only partially impaired in MKR mice (12%, P ≤ 0.05), and FOR‐induced slow‐to‐fast fibre type shift was not blocked at all in these animals. In MKR mice, FOR also restored the lower levels of muscle SDH activity to basal WT values and caused a marked reduction (57%, P ≤ 0.05) in the number of centrally nucleated fibers. CONCLUSIONS: NS/IGF1 signalling is necessary for the anti‐proteolytic and hypertrophic effects of in vivo β(2)‐adrenergic stimulation and appears to mediate FOR‐induced enhancement of protein synthesis. INS/IGF1 signalling only partially contributes to gain in strength and does not mediate fibre type transition induced by FOR. John Wiley and Sons Inc. 2019-04-01 2019-04 /pmc/articles/PMC6463755/ /pubmed/30932373 http://dx.doi.org/10.1002/jcsm.12395 Text en © 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Gonçalves, Dawit A. Silveira, Wilian A. Manfredi, Leandro H. Graça, Flávia A. Armani, Andrea Bertaggia, Enrico O´Neill, Brian T. Lautherbach, Natalia Machado, Juliano Nogara, Leonardo Pereira, Marcelo G. Arcidiacono, Diletta Realdon, Stefano Kahn, C. Ronald Sandri, Marco Kettelhut, Isis C. Navegantes, Luiz Carlos C. Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
title | Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
title_full | Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
title_fullStr | Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
title_full_unstemmed | Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
title_short | Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
title_sort | insulin/igf1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463755/ https://www.ncbi.nlm.nih.gov/pubmed/30932373 http://dx.doi.org/10.1002/jcsm.12395 |
work_keys_str_mv | AT goncalvesdawita insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT silveirawiliana insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT manfredileandroh insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT gracaflaviaa insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT armaniandrea insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT bertaggiaenrico insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT oneillbriant insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT lautherbachnatalia insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT machadojuliano insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT nogaraleonardo insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT pereiramarcelog insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT arcidiaconodiletta insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT realdonstefano insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT kahncronald insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT sandrimarco insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT kettelhutisisc insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth AT navegantesluizcarlosc insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth |